Hookipa Pharma Inc (HOOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has a cash flow conversion efficiency ratio of -0.249x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($28.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hookipa Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hookipa Pharma Inc total liabilities for a breakdown of total debt and financial obligations.
Hookipa Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hookipa Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LX Hausys Ltd Preferred
KO:108675
|
0.096x |
|
Amalgamated Industrial Steel Berhad
KLSE:2682
|
-0.152x |
|
Value8 N.V
AS:PREVA
|
-0.014x |
|
ABERA BIOSCIENCE AB
F:8WK
|
N/A |
|
Putra Rajawali Kencana PT
JK:PURA
|
0.012x |
|
Mobio Technologies Inc
V:MBO
|
0.101x |
|
Mixed Martial Arts Group Limited
NYSE MKT:MMA
|
9.175x |
|
Riley Gold Corp
V:RLYG
|
-0.094x |
Annual Cash Flow Conversion Efficiency for Hookipa Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hookipa Pharma Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see HOOK market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.52 Million | $-11.50 Million | -0.354x | +76.47% |
| 2024-12-31 | $51.21 Million | $-76.98 Million | -1.503x | -134.79% |
| 2023-12-31 | $89.86 Million | $-57.52 Million | -0.640x | -228.19% |
| 2022-12-31 | $102.52 Million | $-20.00 Million | -0.195x | +73.53% |
| 2021-12-31 | $89.59 Million | $-66.02 Million | -0.737x | -192.43% |
| 2020-12-31 | $156.12 Million | $-39.34 Million | -0.252x | +28.81% |
| 2019-12-31 | $117.90 Million | $-41.73 Million | -0.354x | -4.78% |
| 2018-12-31 | $44.40 Million | $-15.00 Million | -0.338x | -220.95% |
| 2017-12-31 | $-42.66 Million | $-11.91 Million | 0.279x | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more